With temperatures dipping below freezing, consider the toll that frost is taking on your skin. The good news is experts from The University of Texas Health Science Center at Houston (UTHealth) can help keep your skin in tip-top condition as the winter weather takes hold.
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit the sale of most flavored electronic cigarettes (e-cigarettes) to age-restricted locations and require age-verification for online sales to lower the use of these products in children. In addition, the FDA plans to restrict the marketing of these products toward youth.
Using an innovative quality improvement project to determine how to design an effective emergency trauma clinical trial, a team of surgeons at The University of Texas Health Science Center at Houston (UTHealth) was able to launch the first-ever study on a high-risk damage control surgery for critical abdominal injuries.
In collaboration with the Houston Health Department and Epic (electronic medical records company), Houston Methodist is the first hospital system in eight U.S. pilot sites to successfully test and launch an approach to electronic case reporting (eCR) that can automatically send case reports directly from a hospital to public health agencies.
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp has demonstrated high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors. The study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.
Antibiotic resistance is predicted to be the No. 1 cause of death in the world by 2050, but a team of scientists and physicians at The University of Texas Health Science Center at Houston (UTHealth) is determined to help stop this grave prediction from becoming a reality.
A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth). It is the first trial of its kind in the world.
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.
When comparing standard-of-care surgical options for women with early-stage cervical cancer, two studies led by researchers at The University of Texas MD Anderson Cancer Center discovered that minimally invasive radical hysterectomy is associated with higher recurrence rates and worse overall survival (OS), compared to abdominal radical hysterectomy.
In its first year, an innovative virtual program has substantially increased mistreated elderly Texans’ access to elder mistreatment and geriatric experts with The University of Texas Health Science Center at Houston (UTHealth).
Beheaded stuffed peppers, graveyard chocolate hummus and creepy crawly pumpkin bars were among the Halloween-themed treats created by students at The University of Texas Health Science Center at Houston (UTHealth) School of Dentistry who were learning how to cook as part of a new program in partnership with UTHealth School of Public Health.
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy.
The Michael & Susan Dell Center for Healthy Living, part of The University of Texas Health Science Center at Houston (UTHealth), announced today a new plan to create a statewide network of researchers, decision-makers, and other key representatives that will give increased access to evidence-based solutions and data.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, suggesting a potential new area of therapeutic investigation. The findings, published in the Oct. 22 online issue of Nature Genetics, were surprising given that MALAT1, a long non-coding RNA (lncRNA), previously was described as a metastasis promoter.
Radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage 4 disease who have not progressed after frontline chemotherapy, a study led by researchers from The University of Texas MD Anderson Cancer Center shows.
An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer and other diseases in which the immune system is compromised. The study, led by Katy Rezvani, M.D., Ph.D., professor, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center, showed marked improvement in three PML patients infused with donor T cells targeting the BK virus. Findings were published in the Oct. 11 online issue of the New England Journal of Medicine.
The phase II study was led by researchers at The University of Texas MD Anderson Cancer Center. Results of the study, the first randomized neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients, are reported in Nature Medicine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right